FOSUN PHARMA: Controlling subsidiary signs licensing agreement with Eisai

36Kr learned that FOSUN PHARMA announced that its controlling subsidiary HENLIUS has signed a licensing agreement with Eisai, granting Eisai the rights to develop, produce, and commercialize the injection of Surufatinib in the licensed region (i.e., Japan) and field (i.e., for the treatment of tumor indications). According to the agreement, Eisai shall pay HENLIUS a non-refundable upfront payment of up to USD 155 million and regulatory milestone payments for the licensed product; based on the annual net sales of the licensed product in the licensed region, Eisai shall pay HENLIUS up to USD 233 million in sales milestone payments as agreed